
1. j clin microbiol. 2018 sep 25;56(10). pii: e00711-18. doi: 10.1128/jcm.00711-18. 
print 2018 oct.

rapid antigen tests influenza: rationale significance fda
reclassification.

green da(1), stgeorge k(2)(3).

author information: 
(1)department pathology & cell biology, columbia university college of
physicians surgeons, new york, new york, usa dag2149@cumc.columbia.edu.
(2)laboratory viral diseases, wadsworth center, new york state department of
health, albany, new york, usa.
(3)department biomedical science, university albany, suny, albany, new
york, usa.

rapid antigen tests influenza, referred rapid influenza diagnostic
tests (ridts), widely used diagnosis influenza since their
introduction 1990s due ease use, rapid results, and
suitability point care (poc) testing. however, issues related the
diagnostic sensitivity assays known decades, these
issues gained greater attention following reports poor performance
during 2009 influenza a(h1n1) pandemic. turn, significant concerns arose
about consequences false-negative results, could pose significant
risks individual patient care public health efforts. response
to concerns, fda convened advisory panel june 2013 discuss
options improve regulation performance ridts. proposed order
was published 22 may 2014, final order published 12 january 2017,
reclassifying ridts class class ii medical devices, additional
requirements comply four new special controls. reclassification a
landmark achievement regulation diagnostic devices infectious
diseases important consequences future diagnostic influenza
testing commercial tests, warranting prompt attention clinical
laboratories, health care systems, health care providers.

copyright Â© 2018 american society microbiology.

doi: 10.1128/jcm.00711-18 
pmcid: pmc6156320
pmid: 29899007  [indexed medline]

